Managing IP is part of the Delinian Group, Delinian Limited, 8 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2023

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

The Netherlands: Ascertaining inventive step in a dosage of tadalafil

Cialis® is a pharmaceutical product for the treatment of erectile dysfunction developed by Lilly ICOS, a joint venture of ICOS Corporation and Eli Lilly and Company. The active pharmaceutical ingredient (API) of Cialis®, tadalafil, inhibits the PDE5 enzyme, just like sildenafil in the better-known Viagra®.

Recently, the District Court of The Hague had to decide whether a pharmaceutical unit dosage composition for a maximum daily dosage of 5mg of tadalafil for the treatment of a sexual dysfunction, as claimed in ICOS's patent EP1173181, involves an inventive step. Teva Pharmaceuticals Europe, claiming invalidity of the patent before the court, argued that this dosage composition is obvious in view of an earlier patent publication by ICOS (WO 97/03675).

Contrary to ICOS's submissions, by disclosing the use of tadalafil for sexual dysfunction, this earlier document incentivises the skilled person to develop a second in class drug for this indication and the skilled person would accordingly start clinical trials. As such, the court reasoned that the case comes down to the question of which dosages would be tested in a phase IIb clinical trial and whether 5mg would be part of this trial.

Following this reasoning, the court judged that the skilled person could then walk down two one-way streets, which would both inevitably lead to the dosage unit composition of 5 mg. Going down a first street, the skilled person would find pharmaceutical data in phase I clinical trial studies which would, together with known efficacy data for sildenafil in Viagra®, enable him to make the calculated estimation that a 5mg daily dosage should be included in phase IIb clinical trial tests. The court then further argued that, even if the skilled person would not take this street, but instead would turn into phase IIb clinical trial studies with daily dosages of 25, 50 and 100 mg, the skilled person would have found a constant efficacy of tadalafil at these dosages and would accordingly have lowered the dosage to reduce side effects. As such, either street would lead the skilled person to an effective daily dosage of 5mg with minimal side effects.

Therefore, in the court's decision, all roads obviously lead to Cialis®.

Henri van Kalkeren


V.O.Carnegieplein 5, 2517 KJThe HagueThe NetherlandsTel: +31 70 416 67 11Fax: +31 70 416 67 99info@vo.euwww.vo.eu

more from across site and ros bottom lb

More from across our site

12th annual awards announces winners
Sources say parties in trademark cases could tussle over the meaning of source identifier and whether surveys are fair, following the US Supreme Court ruling
We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP
In-house sources say the UPC’s determinations on validity, injunctions, and damages could dictate whether companies leave their patents in or out
Business is quiet so far but the UPC has everything it needs to attract patentees, panellists at Managing IP’s IP & Innovation Summit argued yesterday, June 7
Reviewing the list of automatically qualifying degrees every three years is a great idea and should bring more tech-savvy people to the bar
A Foss Patents blog post revealed that Mr Justice Marcus Smith handed down his judgment in Optis v Apple on May 10
Witnesses during a committee hearing criticised proposals to increase some fees by as much as 400%
Sources say they are likely to hire external counsel that can create a lasting first impression but might turn their backs on lawyers who have nothing new to offer
Varuni Paranavitane, of counsel at Finnegan, examines recent decisions by US and UK courts to demonstrate the proof of infringement that was required